pLenti-CD74-ROS1 nonmutant
(Plasmid
#183813)
-
PurposeExpress CD74-ROS1 fusion (C6;R34) in mammalian cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 183813 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLenti
- Backbone size w/o insert (bp) 7877
- Total vector size (bp) 9430
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert 1
-
Gene/Insert nameROS Proto-Oncogene 1, Receptor Tyrosine Kinase
-
Alt nameROS1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1488
-
GenBank IDNP_002935
-
Entrez GeneROS1 (a.k.a. MCF3, ROS, c-ros-1)
- Promoter CMV
-
Tag
/ Fusion Protein
- The fusion protein of CD74 exon 1-6 and ROS1 exon 34-43
Cloning Information for Gene/Insert 1
- Cloning method TOPO Cloning
- 5′ sequencing primer T7 (Common Sequencing Primers)
Gene/Insert 2
-
Gene/Insert nameCD74 molecule
-
Alt nameCD74
-
SpeciesH. sapiens (human)
-
Insert Size (bp)625
-
GenBank IDNM_001025159.3
-
Entrez GeneCD74 (a.k.a. CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33)
- Promoter CMV
-
Tag
/ Fusion Protein
- The fusion protein of CD74 exon 1-6 and ROS1 exon 34-43
Cloning Information for Gene/Insert 2
- Cloning method TOPO Cloning
- 5′ sequencing primer T7 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLenti-CD74-ROS1 nonmutant was a gift from Aaron Hata (Addgene plasmid # 183813 ; http://n2t.net/addgene:183813 ; RRID:Addgene_183813) -
For your References section:
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8. 10.1158/1078-0432.CCR-21-0032 PubMed 33685866